Accretion Pha. (ACCPL)

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Piotroski F-Score of 7/9 indicates strong profitability and financial health.
• ROCE of 46.36% reflects highly efficient use of capital.
• Explosive growth: sales up 135.67%, profit up 93.09%, with a PEG of 0.08.
• Promoter holding of 73.52% aligns management interest with minority shareholders.
• Low P/E of 8.69 provides valuation support if growth persists.

Concerns

• No book value, ROE, or debt/equity data; balance-sheet transparency is inadequate for Graham-style analysis.
• Share price is down roughly 54% from its 52-week high; the market may be pricing in headwinds not visible in the quarterly figures.
• No dividend means investors rely entirely on growth and capital appreciation.
• Small market cap of ₹79 Cr and high promoter holding can lead to volatility and liquidity risk.

AI Analysis

Looking at Accretion Pha., the first thing that catches my eye is the price: ₹89.75, less than half its 52-week high of ₹196.75. That is exactly the kind of decline that makes a value hunter pause. A P/E of 8.69 for a pharmaceutical company with 135.67% sales growth and 93.09% profit growth is remarkable; the PEG ratio of 0.08 would make Graham's eyebrows rise. But the market is not always wrong. I need to know why this small-cap, ₹79 Cr company, has been cut down. The latest quarter shows sales of ₹44 Cr and net profit of ₹5 Cr; if that pace continues, earnings annualise to roughly ₹20 Cr, making the stock look even cheaper than the trailing P/E. Yet I must be cautious: a single quarter proves nothing in pharma, and the data provided lacks book value, ROE, and debt/equity. Benjamin Graham always insisted on knowing the balance sheet. High promoter holding of 73.52% is a double-edged sword—alignment is good, but thin liquidity can cause sharp moves. ROCE of 46.36% is excellent and Piotroski F-Score of 7/9 suggests solid fundamentals, but with no dividend, every rupee of returns must come from growth and eventual re-rating. The company is clearly a fast grower, not a stalwart. As an investor, I would demand a wide margin of safety because small pharma names often lack durable moats. The price decline may be an opportunity—or a warning. I will not chase; I will wait for more balance-sheet transparency and evidence that 135% growth is sustainable. In this market, patience is the best arbitrageur.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer